• Anteris’ study is progressing well at the one year and 30-day time points
  • Imugene’s Phase 1 trial has progressed to the next cohort level
  • Nyrada has a new lead drug

 

Regenerative medicine biotech Anteris Technologies (ASX:AVR) has just presented the latest data from the DurAVR First-In-Human Study at the TVT Conference.

Results show that DurAVR THV continues to maintain excellent haemodynamic performance at one year and 30-day time points.

During the study, DurAVR THV was successfully implanted in 100% of the patients, with no device-related complications.

The first 12 patients have completed their one-year follow-up, and results demonstrated sustained haemodynamic performance. All 20 study patients meanwhile have reached their 30-day follow-up, showing results consistent with data previously reported.

“This is another step forward as we continue building upon the body of evidence that supports the use of DurAV THV in patients with aortic stenosis,” said chief medical officer, Dr Chris Meduri.

The DurAVR is a 3D single-piece aortic heart valve replacement which the company believes will be a game-changer in treating aortic stenosis patients.

 

Imugene progresses to next cohort

Imugene (ASX:IMU) announced that its Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of cancer-killing virus CF33-hNIS (VAXINIA) has progressed to the next cohort level.

The trial has now cleared cohort 3, and opened cohort 4 of the IV arm of the monotherapy dose escalation.

In addition, cohort 1 of the IV arm of the combination study with Pembrolizumab has also been cleared, allowing cohort 2 to be opened.

 

Nyrada’s new lead drug

Nyrada (ASX:NYR) says its new brain injury drug candidate NYR-BI03 will be advanced instead of NYR-BI02, due to demonstrated superior potency and safety profile, overcoming limitations identified with NYR-BI02 during preclinical studies.

The company said it has reviewed over 200 available compounds generated by NYR-BI03, a closely related analogue of NYR-BI02.

The study indicated that NYR-BI03 has a superior safety profile along with better potency on the TRPC ion channel protein target.

This means that NYR-BI03 has now become Nyrada’s new lead brain injury drug candidate.

Meanwhile, Starpharma (ASX:SPL) CEO Dr Jackie Fairley announced that she will retire in 2024, after being in the position since 2006.

The board said Fairley will remain in the role until a successor is ready to commence.

 

Share prices today:

 

 

Read MoreBiotech

Featured Companies

You might be interested in